Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cediranib maleate

The maleate salt of an indole ether quinazoline derivative with antineoplastic activities. Competing with adenosine triphosphate, cediranib binds to and inhibits all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	AZD2171 maleate
US brand name:	Recentin
Foreign brand name:	Recentin
Code name:	AZD2171
Chemical structure:	4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1- yl)propoxy]quinazoline (2Z)-but-2-enedioate quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1- pyrrolidinyl)propoxy]-, (2Z)-2-butenedioate (1:1)

cediranib maleate

Search NCI's Drug Dictionary